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Abstract
Background: In an effort to locate susceptibility genes for type 1 diabetes (T1D) several genome-wide linkage scans
have been undertaken. A chromosomal region designated IDDM10 retained genome-wide significance in a combined
analysis of the main linkage scans. Here, we studied sequence polymorphisms in 23 Mb on chromosome 10p12-q11,
including the putative IDDM10 region, to identify genes associated with T1D.
Results: Initially, we resequenced the functional candidate genes, CREM and SDF1, located in this region, genotyped 13
tag single nucleotide polymorphisms (SNPs) and found no association with T1D. We then undertook analysis of the
whole 23 Mb region. We constructed and sequenced a contig tile path from two bacterial artificial clone libraries. By
comparison with a clone library from an unrelated person used in the Human Genome Project, we identified 12,058
SNPs. We genotyped 303 SNPs and 25 polymorphic microsatellite markers in 765 multiplex T1D families and followed
up 22 associated polymorphisms in up to 2,857 families. We found nominal evidence of association in six loci (P = 0.05
– 0.0026), located near the PAPD1 gene. Therefore, we resequenced 38.8 kb in this region, found 147 SNPs and
genotyped 84 of them in the T1D families. We also tested 13 polymorphisms in the PAPD1 gene and in five other loci
in 1,612 T1D patients and 1,828 controls from the UK. Overall, only the D10S193 microsatellite marker located 28 kb
downstream of PAPD1 showed nominal evidence of association in both T1D families and in the case-control sample (P =
0.037 and 0.03, respectively).
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BMC Genetics 2007, 8:24 http://www.biomedcentral.com/1471-2156/8/24Conclusion: We conclude that polymorphisms in the CREM and SDF1 genes have no major effect on T1D. The weak
T1D association that we detected in the association scan near the PAPD1 gene may be either false or due to a small
genuine effect, and cannot explain linkage at the IDDM10 region.
Background
Type 1 diabetes (T1D) is the second most common
chronic disease in children. It develops as a result of a
complex interaction of genetic and environmental factors
leading to the immune-mediated destruction of the insu-
lin-producing pancreatic β-cells. Genetic predisposition
has a significant role in T1D as suggested by familial clus-
tering of the disease and increased concordance among
monozygotic twins [1]. The identification and localiza-
tion of susceptibility genes for complex traits or common
diseases has made slow progress, owing to many factors
including small effect sizes, incomplete knowledge of the
polymorphism content of the genome and its patterns of
linkage disequilibrium and lack of inexpensive genotyp-
ing technologies. One approach to narrowing down to
specific genome regions that might contain a susceptibil-
ity gene or genes has been to carry out linkage studies in
affected sib-pair families. In contrast to monogenic dis-
eases, this approach has had limited success in multifacto-
rial diseases.
Nevertheless, in T1D, combined analyses of several stud-
ies provided evidence for four linked regions, the major
locus MHC on 6p21 (previously designated IDDM1),
10p14-q11 (IDDM10), 2q31-q33 (IDDM7 and IDDM12)
and 16q22-q24 [2]. Here we undertook analysis of
sequence polymorphisms in the putative IDDM10 region,
comprising 23 Mb region on the chromosome 10p12-
q11. We have identified a large number of single nucle-
otide polymorphisms (SNPs) and performed an associa-
tion scan of this region in a large collection of T1D
families, as well as unrelated patients and controls.
Results
Initially, in order to identify T1D genes in the IDDM10
region we adopted a candidate gene approach. Previously
we examined the GAD2 gene, which encodes a major T1D
autoantigen GAD65 protein, and found no evidence of
association [3]. Here we resequenced and studied associa-
tion of two candidate genes, CREM and SDF1, which also
map to this region. The cyclic adenosine 5'-monophos-
phate responsive element modulator (CREM) has been
shown to bind to the Interleukin-2 gene promoter and
suppress expression of this cytokine [4], which is critical
for the initiation and termination of the immune
response as well as for T cell development. Increased
CREM expression was found in T cells of patients with
another autoimmune disease, systemic lupus erythemato-
sus [5]. By resequencing the CREM gene we identified 32
SNPs, including 13 novel SNPs (Supplementary Table 1,
see Additional file 1). We selected six tag SNPs and geno-
typed them in 1,612 T1D patients and 1,828 controls
from the UK. We found a multi locus P = 0.98, indicating
that common variants of CREM do not affect T1D suscep-
tibility in a major way.
By resequencing the cytokine stromal cell-derived factor 1
(SDF1 or CXCL12) gene we identified 33 variants, includ-
ing two insertion/deletion polymorphisms, 21 of which
were novel (Supplementary Table 2, see Additional file 2).
We selected six tag SNPs, genotyped them in 1,612 cases
and 1,828 controls and found no association (multi locus
P = 0.67). We also tested SNP rs1801157, also known as
3'A(801G>A), in the evolutionary conserved 3' untrans-
lated segment of SDF1 that previously had been associ-
ated with early onset of T1D [6,7]. We attempted to
replicate these findings and genotyped rs1801157 in
1,800 T1D families from the UK, USA and Norway. The A
allele and AA genotype frequencies were very similar to
those reported previously (19.4% and 5.8%, respectively).
The transmission disequilibrium test revealed no associa-
tion with T1D (507 transmitted A alleles and 530 untrans-
mitted, P = 0.47; relative risk for AA genotype = 1.01, 95%
CI = 0.87–1.16, P =0.89). Even though we obtained no
evidence of association we subdivided the families by age-
at-onset and by HLA-DRB1 genotype because the two pre-
vious studies had carried out subgroup analyses. How-
ever, we found no association in any subgroup (data not
shown).
We then conducted a comprehensive genetic analysis of
the whole IDDM10 region in order to systematically iden-
tify new T1D gene(s). As part of the Human Genome
Project (HGP) the Wellcome Trust Sanger Institute con-
structed a single tile path, i.e. set of overlapping BACs
derived from two different libraries [8,9]. The overlaps
between clones in this tile path were checked for SNPs and
those were deposited in the dbSNP database previously
[10]. In order to discover additional novel SNPs in the
IDDM10 region we constructed a second tile path that
covers the whole region using clones from both BAC
libraries, so that finished genome sequence from one
library was complemented by a clone from the second
library, i.e. from a different individual. This second tile
path was then shotgun sequenced. Thus, we revealed
additional polymorphic sites located outside BAC over-
laps in the initial HGP tile path. In total we identified and
submitted to dbSNP 12,058 SNPs, of which 10,808 werePage 2 of 8
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including 1,320 SNPs that were novel, i.e. not present in
dbSNP build 120. These SNPs contributed substantially to
the polymorphism content of the IDDM10 region.
We then screened for association with T1D sequence pol-
ymorphisms between 21.0 Mb and 44.3 Mb of chromo-
some 10 (NCBI genome build 34) that include the
IDDM10 region. In total 303 SNPs and 25 polymorphic
microsatellite markers/short tandem repeats (STRs) were
genotyped in up to 765 families with two affected off-
spring (Supplementary Table 3, see Additional file 3). This
sample includes families in which linkage of IDDM10 was
characterized initially [11-13]. We found 14 polymor-
phisms in nine loci showing nominal evidence of associ-
ation with T1D (P < 0.05). In order to investigate these
results further, we genotyped these polymorphisms in an
additional set of T1D families (Table 1). In the combined
analyses of up to 2,857 families we found some evidence
for T1D association of D10S193, rs1963187 and
rs2480285 (P = 0.037, 0.0074 and 0.0026, respectively),
which are clustered in a 97 kb region (coordinates: chr10;
30,577,375..30,674,697; NCBI genome build 34). Their
association with the disease was largely independent of
each other (between rs1963187 and rs2480285 r2 = 0.24,
while between risk associated allele 226 of D10S193 and
rs1963187 and rs2480285 r2 = 0 and 0.01, respectively).
Two genes localize within 150 kb of the D10S193,
rs1963187 and rs2480285 markers (Figure 1 and [14]).
The polyA polymerase associated domain containing 1
(PAPD1) gene encodes a protein with a nucleic acid bind-
ing PAP/25A-associated domain. Associated polymor-
phisms flank PAPD1, while the second gene, known as
MAP3K8 (mitogen-activated protein kinase kinase kinase
8) is located 50 – 177 kb away from the associated poly-
morphisms. We then searched for novel sequence poly-
morphisms in this region. Using a panel comprising eight
Caucasian individuals we resequenced 38.8 kb in the
177.2 kb region between D10S193 and exon 9 of the
Table 1: Association analysis in the extended T1D family set.
Gene Polymorphism Allele 1/2c Affected offspring Allele 1, Transmitted (%) Allele 1, Non-transmitted (%) P-value TDT Allele 1, frequency d
PAPD1
Rs639299a G/A 2029 777 (48.2) 834 (51.8) 0.16 0.69
rs1963187a A/T 2383 272 (56.1) 213 (43.9) 0.0074 0.95
rs2480285a G/A 2642 785 (46.3) 909 (53.7) 0.0026 0.21
D10S1426a 1401 0.21
*158 502 (52.7) 450 (47.3) 0.092 0.27
*162 502 (48.4) 535 (51.6) 0.31 0.33
*166 420 (52.3) 383 (47.7) 0.19 0.23
D10S193a 1932 0.037
*220 587 (46.6) 673 (53.4) 0.015 0.28
*224 781 (52.2) 716 (47.8) 0.093 0.35
*226 363 (55.1) 296 (44.9) 0.0091 0.11
*228 185 (47.8) 202 (52.2) 0.39 0.07
rs540994 b A/C 2096 941 (51.4) 889 (48.6) 0.22 0.45
ss48399034b A/T 2124 178 (58.4) 127 (41.6) 0.0035 0.96
rs1047991b G/A 2382 849 (48.1) 916 (51.9) 0.11 0.73
rs11818836b A/G 2087 958 (52.2) 876 (47.8) 0.056 0.45
ss48399025b A/C 2284 388 (54.0) 330 (46.0) 0.030 0.90
ss48399036b A/G 3207 137 (55.0) 112 (45.0) 0.11 0.02
ss48399044b T/A 2061 461 (46.6) 529 (53.4) 0.031 0.83
NRP1
rs13324a A/G 2134 826 (50.6) 806 (49.4) 0.62 0.30
rs1048804a A/G 2047 661 (47.7) 725 (52.3) 0.086 0.75
rs1010826a A/G 2125 737 (51.9) 683 (48.1) 0.15 0.24
MYO3A
rs1339816 a A/G 2107 820 (47.7) 898 (52.3) 0.060 0.35
rs2096176 a A/G 2116 893 (47.6) 984 (52.4) 0.036 0.42
HNRPF
rs1416226a A/G 2090 728 (53.5) 632 (46.5) 0.0092 0.23
SVIL
rs2274494a A/G 2152 894 (47.5) 987 (52.5) 0.032 0.37
rs11600a A/G 2147 432 (47.5) 477 (52.5) 0.14 0.13
Intergenic
rs787025 a A/C 2038 237 (45.6) 283 (54.4) 0.044 0.06
BMS1L
rs787795a A/G 2102 537 (53.4) 469 (46.6) 0.032 0.86
a – polymorphism genotyped in the initial scan, b – polymorphisms genotyped after being identified by resequencing of the PAPD1-MAP3K8 gene 
region, c – alleles encoded as 1and 2 for SNPs or as size of an allele for STRs, d – allele frequency among parents of T1D patients from the UK is 
shown; TDT – transmission disequilibrium testPage 3 of 8
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iants we resequenced exons, exon-intron boundaries and
putative regulatory regions of the PAPD1 gene using a
panel of 96 T1D patients (each representing one of the UK
multiplex families in which affected sibs share both chro-
mosomes identical-by-descent in the IDDM10 region). In
total we found 147 SNPs (Supplementary Table 4, see
Additional file 4).
Then, in addition to the five polymorphisms (two STRs
and three SNPs) in the PAPD1-MAP3K8 region that were
already genotyped, we tested 84 SNPs identified by rese-
quencing. At first we studied association in 458 UK fami-
lies (Supplementary Table 5, see Additional file 5).
Subsequently, seven SNPs that were suggestively associ-
ated in these UK families (P = 0.012 – 0.073) were geno-
typed in the extended set of up to 2,857 T1D families.
Thus, overall we studied 12 polymorphisms in the
PAPD1-MAP3K8 region in all available T1D families. We
found that alleles of six SNPs that localize in the PAPD1
gene show nominal evidence of association with T1D risk
or protection (P = 0.0026 – 0.031, Table 1). Then we gen-
otyped an additional sample of 1,693 unrelated T1D
patients and 1,805 controls from the UK (Table 2) for six
PAPD1 polymorphisms that were associated in the previ-
ous analysis of the extended family set. We found that
only microsatellite marker D10S193 located 28 kb down-
stream of PAPD1 was weakly associated in this sample (P
= 0.03, Table 2). Thus allele 226 of D10S193 was weakly
associated with T1D risk both in the families (relative risk
[RR] = 1.15, P = 0.019) and in the case-control analysis
(OR = 1.16, P = 0.078). Another D10S193 allele 228 was
associated with protection from T1D in cases and controls
(OR = 0.73, P = 0.006), but not in the families (RR = 0.96,
P = 0.59).
Additionally, we further studied seven SNPs in the
MYO3A, HRNPF, NRP1 and SVIL gene regions that have
shown some evidence of association in the T1D families
(P = 0.0092 – 0.04, Table 1). We genotyped these SNPs in
1,693 T1D patients and 1,805 controls, but found no
association with T1D (Table 2).
Discussion
Overall, the association signals that we detected in the
IDDM10 region near the PAPD1 gene did not reach
genome-wide significance levels, despite having tested
large samples of T1D families, cases and controls. This
association could be spurious or could indicate a small
genuine effect located near the PAPD1 gene that we did
not have statistical power to demonstrate at a genome-
wide significance level. Such an effect could not explain
the reported evidence of T1D linkage at this region of
chromosome 10, λs = 1.12. If IDDM10 is a true disease
locus, it could be caused by a single common contributory
variant with strong effect (such as OR = 2 and minor allele
frequency of 0.2) or, more likely, by a number of variants
with smaller effects located in this region. Therefore, fur-
ther association studies in datasets that are powered to
identify weak genetic effects (e.g. OR = 1.3 – 1.5) are
needed to discover these type 1 diabetes genes.
Table 2: Association analysis in the 1,693 T1D patients and 1,805 controls from the UK.
Gene Allele Type 1 diabetes patients Controls MAF
Polymorphism 1/2 11 (%) 12 (%) 22 (%) 11 (%) 12 (%) 22 (%) T1D Controls OR for allele 1 (95% CI) P-value
PAPD1
rs2480285 G/A 82 (5.0) 544 (33.4) 1002 (61.5) 59 (3.4) 600 (34.9) 1060 (61.7) 0.22 0.21 1.05 (0.94 – 1.18) 0.39
ss48399025 A/C 1375 (81.4) 296 (17.5) 19 (1.1) 1469 (81.4) 326 (18.1) 10 (0.6) 0.10 0.1 0.97 (0.83 – 1.13) 0.68
ss48399034 A/T 1528 (90.6) 155 (9.2) 3 (0.2) 1620 (92.3) 133 (7.6) 2 (0.1) 0.05 0.04 0.81 (0.64 – 1.02) 0.076
ss48399036 A/G 0 (0.0) 64 (3.8) 1629 (96.2) 0 (0.0) 60 (3.3) 1734 (96.7) 0.02 0.02 1.13 (0.79 – 1.62) 0.49
rs1963187 A/T 1457 (89.1) 170 (10.4) 8 (0.5) 1564 (89.6) 175 (10.0) 7 (0.4) 0.06 0.05 0.95 (0.77 – 1.17) 0.62
D10S193 226/non 226 21 (1.3) 293 (18.5) 1270 (80.2) 15 (1.0) 261 (16.6) 1297 (82.5) 0.11 0.09 1.16 (0.98 – 1.37) 0.078
D10S193 228/non 228 4 (0.3) 158 (10.0) 1422 (89.8) 13 (0.8) 195 (12.4) 1365 (86.8) 0.05 0.07 0.73 (0.59 – 0.90) 0.0031
NRP1
rs1048804 A/G 962 (57.7) 605 (36.3) 100 (6.0) 1068 (59.9) 636 (35.7) 80 (4.5) 0.24 0.22 0.9 (0.81 – 1.01) 0.071
MYO3A
rs1339816 A/G 183 (11.3) 686 (42.3) 751 (46.4) 190 (11.2) 731 (43.1) 774 (45.7) 0.32 0.33 0.99 (0.89 – 1.09) 0.79
rs2096176 A/G 312 (18.7) 790 (47.2) 570 (34.1) 310 (17.5) 872 (49.1) 593 (33.4) 0.42 0.42 1.01 (0.92 – 1.11) 0.83
HNRPF
rs1416226 A/G 101 (6.1) 574 (34.4) 993 (59.5) 91 (5.2) 629 (36.0) 1028 (58.8) 0.23 0.23 1.0 (0.90 – 1.12) 0.95
SVIL
rs2274494 A/G 230 (13.7) 784 (46.9) 659 (39.4) 214 (12.2) 847 (48.2) 698 (39.7) 0.37 0.36 1.04 (0.94 – 1.15) 0.42
rs11600 T/C 32 (1.9) 372 (22.3) 1261 (75.7) 25 (1.4) 397 (22.3) 1362 (76.3) 0.13 0.13 1.05 (0.91 – 1.21) 0.48
Intergenic
rs787025 T/G 8 (0.5) 226 (13.6) 1433 (86.0) 6 (0.3) 237 (13.2) 1549 (86.4) 0.07 0.07 1.05 (0.87 – 1.26) 0.62
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism.Page 4 of 8
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The PAPD1-MAP3K8 gene region on chromosome 10Figure 1
The PAPD1-MAP3K8 gene region on chromosome 10. Tracks indicate (from top to bottom): position in the human 
genome chromosome 10, NCBI build 34; annotated genes; regions where resequencing of the amplified fragments has been 
attempted; sequenced BAC clones; SNPs identified in the clone overlaps; polymorphisms genotyped in up to 765 UK and USA 
families with two affected offspring; SNP rs or ss numbers; a plot showing -log(P-value) for association in up to 765 families 
with red line at 1.3 corresponding to P = 0.05; linkage disequilibrium (LD) plots for SNPs with minor allele frequency > 0.1 
showing pairwise LD by colour ranging from red (high D') or dark green (high r2), indicating strong LD, to white, indicating 
weak or no LD between SNPs. LD plots have been generated using Haploview [27].
BMC Genetics 2007, 8:24 http://www.biomedcentral.com/1471-2156/8/24Conclusion
We identified a large number of SNPs for genetic studies
in the IDDM10 region using a novel sequencing strategy,
performed a first T1D association scan of this region and
eliminated the possibility that two functional candidate
genes, CREM and SDF1, have major effect on T1D. The
weak association signal near the PAPD1 gene detected in
the association scan may be either false or due to a small
genuine effect, and cannot explain the previously
observed strong linkage in the IDDM10 region.
Methods
Double tile path construction and shotgun sequencing
We constructed a double tile path between 21,022,316
and 44,323,745 bp of chromosome 10 (NCBI build 34)
from two bacterial artificial chromosome (BAC) libraries,
RPCI-11 and RPCI-13, and sequenced selected clones at
the Wellcome Trust Sanger Institute. In total the shotgun
tile paths comprised 110 RPCI-11 clones and 86 RPCI-13
clones that represent 12.6 Mb of overlap sequence. In
addition to the finished sequence of chromosome 10, we
shotgun sequenced to draft quality complementary clones
from the other library in the tile path. In 1,060 overlaps
the RPCI-11 clone was completely finished and in 76
overlaps the RPCI-13 clone was completely finished. Of
the unfinished clones 77 (98.72%) were in multiple
smaller contigs, i.e. draft quality.
SNP identification
Repeats were masked using RepeatMasker [15] and then
masked sequences were used in pair-wise sequence align-
ments by Sequence Search and Alignment by Hashing
Algorithm (SSAHA) to map clone sequences and find
SNPs [16]. Overlaps ≥ 2 kb were considered for SNP iden-
tification. We only checked overlaps between clones in
different tile paths as overlaps from the finished tile path
had been checked for SNPs previously. A file of overlap
pairs was derived and used as an input for a script that
calls SSAHA and then parses the resulting alignments. To
avoid false SNP calling due to misalignment, clusters of
five or more SNPs were rejected when each one was less
then 10 bp away from neighboring SNPs. We then
mapped SNPs on the human genome consensus path
(NCBI build 34) using the mapping information from the
clone and the SSAHA algorithm. The tile paths and SNPs
can be viewed on our website [14]. Information on all
polymorphisms has been submitted to dbSNP [17].
Subjects
The study was done according to the principles of the Hel-
sinki Declaration. We obtained permission from relevant
ethical committees and informed consent from the partic-
ipating subjects. Initially, we genotyped 329 polymor-
phisms in up to 765 families of Caucasian ethnic group,
each with two children affected with T1D comprising 458
Diabetes UK Warren families and 307 The Human Biolog-
ical Data Interchange (HBDI) families. An extended set of
families with at least one affected child comprised fami-
lies from the UK (n = 1,781, including 458 Diabetes UK
Warren families), Norway (n = 359), Romania (n = 352)
and the USA (n = 365, including 307 HBDI families).
Therefore, in total we studied 2,857 T1D families; exact
number of affected offspring genotyped for each SNP is
shown in Table 1. Assuming multiplicative genetic model,
this extended set of T1D families provides over 80%
power to detect genetic effect with odds ratios (OR) of
1.25 and 1.5 for alleles at 40% and 7%, respectively, at  α
= 10-6. Additionally we studied an independent sample of
1,693 T1D patients collected across the UK and 1,828
control subjects that were selected from the 1958 British
Birth cohort [18]. This case-control collection would have
over 99% power to detect OR = 1.25 and 1.5 for alleles at
40% and 7%, respectively, at α = 0.05.
Candidate gene resequencing and genotyping
We designed primers using Primer3 [19], amplified
genomic DNA by PCR and sequenced PCR fragments with
an ABI Big Dye Terminator v3.1 kit and an ABI3700 capil-
lary sequencer (ABI, Foster City, CA). Sequence reads were
aligned using the Staden package [20]. We resequenced in
32 individuals all CREM and SDF1 exons, exon-intron
boundaries, and up to 3 kb upstream and downstream of
the gene. All identified SNPs have been submitted to
dbSNP [17]. SNP genotyping was carried out using
Invader (Third Wave Technologies, Madison, WI), Taq-
Man (Perkin Elmer Applied Biosystems, Foster City, CA)
or BeadArray (Illumina Inc, San Diego, CA). Microsatellite
markers were genotyped as described elsewhere [13].
Statistical analysis
We assessed genotype frequency among parents for each
polymorphism using Arlequin version 2.000 [21] and
found no unexpected deviation from the Hardy-Weinberg
equilibrium (P > 0.01). Statistical analysis was carried out
within STATA version 8.1 [22]. Tag SNPs that capture
common allelic variation (MAF > 0.03) with r2 ≥ 0.8 were
selected using htstep, htsearch and haptag programs
within Stata [23,24]. When a tag SNP approach was taken,
we used a global association multilocus test using mlpop
program in Stata. It tests for association between the dis-
ease and the tag SNPs due to linkage disequilibrium with
one or more causal variants in the region. This test con-
trasts the allele frequencies of a non-redundant set of tag
SNPs between cases and controls by use of Hotelling's T2
test [25,26]. We did not apply multiple testing corrections
in this study and all P-values reported are uncorrected.
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